Glycyrrhizic Acid Mitigates 2nd Round Radiotherapy-Induced Severe Lung Injury: A Case Report
1Fujian Platform for Medical Research at First Affiliated Hospital; Fujian key Lab of ; Individualized Active Immunotherapy; Key Lab of Radiation Biology of Fujian Province Universities, Fuzhou, China
- *Corresponding Author:
- Lurong Zhang
Fujian Key Lab of Individualized Active Immunotherapy and Key Lab of Radiation Biology
Department of Radiation Biology
E-mail: [email protected] or [email protected]
Received Date: June 19, 2017; Accepted Date: June 23, 2017; Published Date: July 07, 2017
Citation: Zhang W, Hong J, Lin J, Okunieff P, Zhang L (2017) Glycyrrhizic Acid Mitigates 2nd Round Radiotherapy-Induced Severe Lung Injury: A Case Report. Lung Dis Treat 3:125. doi: 10.4172/2472-1018.1000125
Copyright: © 2017 Zhang W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Irradiation (IR) has become more important and effective therapeutic approach for cancer in chest (lung, breast and esophagus), however, IR-induced pneumonitis/fibrosis is still the bottle-neck for using higher IR dose to more effectively eradicate cancer cells, since there is no drug to treat the companion IR-injury toxicity. Glycyrrhizic Acid (GLA) has been used to treat hepatitis and liver fibrosis for almost 3 decades in Asia. It has no lethal dose in animal and no obvious side effect in human, which allows for 2 to 3 months use to imitate chronic fibrosis. Here we report for the first time that while GLA was used to treat the liver damage caused by chemotherapy, it presented a surprising mitigation effect on a 2nd round IR treatment-induced severe lung injury in a recurrent stage B (T2N3M0) lung cancer patient who had severe pneumonitis during the 1st round IR therapy. Combined with the fact that GLA effectively mitigates IR induced pneumonitis/fibrosis in animal model, we conclude that GLA is a potential good candidate to be developed as anti-IR lung injury drug.